Anemia and diabetic nephropathy

Current Diabetes Reports

Volumn 6, Issue 6, 2006, Pages 469-472

  Ritz, Eberhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; IRBESARTAN; LOSARTAN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIALYSIS; DISEASE COURSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPOXEMIA; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MICROANGIOPATHY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; POLYNEUROPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ANEMIA; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ERYTHROPOIETIN; HEART DISEASES; HUMANS;

EID: 33845379957     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0081-0     Document Type: Review

References (47)

1. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
2. Ritz E, Haxsen V: Diabetic nephropathy and anaemia. Eur J Clin Invest 2005, 35(suppl 3):66-74.
3. Bosman DR, Winkler AS, Marsden JT, et al.: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001, 24:495-499.
4. Astor BC, Muntner P, Levin A, et al.: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002, 162:1401-1408.
5. Lorber D, Reddan D: Clinical characteristics of chronic kidney disease patients with and without diabetes: a sub-analysis of the PAERI study. Clin Nephrol 2006, 66:11-16.
6. Vlagopoulos PT, Tighiouart H, Weiner DE, et al.: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005, 16:3403-3410.
7. Stevens PE, O'Donoghue DJ, Lameire NR: Anaemia in patients with diabetes: unrecognised, undetected and untreated? Curr Med Res Opin 2003, 19:395-401.
8. Cotroneo P, Maria Ricerca B, Todaro L, et al.: Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes Metab Res Rev 2000, 16:172-176.
9. Spallone V, Maiello MR, Kurukulasuriya N, et al.: Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric type 2 diabetic patients? Diabet Med 2004, 21:1174-1180.
10. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
11. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al.: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004, 27:195-200.
12. Thomas MC, Cooper ME, Tsalamandris C, et al.: Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005, 165:466-469.
13. Mohanram A, Zhang Z, Shahinfar S, et al.: Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004, 66:1131-1138.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
15. Babazono T, Hanai K, Suzuki K, et al.: Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia 2006, 49:1387-1393.
16. Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000, 58:2351-2366.
17. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17:17-25.
18. Inomata S, Itoh M, Imai H, Sato T: Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997, 75:426-430.
19. Rosenberger C, Mandriota S, Jurgensen JS, et al.: Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002, 13:1721-1732.
20. Garcia DL, Anderson S, Rennke HG, Brenner BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 1988, 85:6142-6146.
21. Qiao Q, Keinanen-Kiukaanniemi S, Laara E: The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997, 50:153-158.
22. Davis MD, Fisher MR, Gangnon RE, et al.: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998, 39:233-252.
23. Shorb SR: Anemia and diabetic retinopathy. Am J Ophthalmol 1985, 100:434-436.
24. Watanabe D, Suzuma K, Matsui S, et al.: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005, 353:782-792.
25. Junk AK, Mammis A, Savitz SI, et al.: Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002, 99:10659-10664.
26. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
27. Sinclair SH, DelVecchio C, Levin A: Treatment of anemia in the diabetic patient with retinopathy and kidney disease. Am J Ophthalmol 2003, 135:740-743.
28. Sinclair SH, Malamut R, Delvecchio C, Li W: Diabetic retinopathy: treating systemic conditions aggressively can save sight. Cleve Clin J Med 2005, 72:447-454.
29. Bianchi R, Buyukakilli B, Brines M, et al.: Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 2004, 101:823-828.
30. Hassan K, Simri W, Rubenchik I, et al.: Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 2003, 16:121-125.
31. Lipton SA: Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med 2004, 350:2516-2517.
32. Foley RN, Culleton BF, Parfrey PS, et al.: Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997, 40:1307-1312.
33. Abramson JL, Jurkovitz CT, Vaccarino V, et al.: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003, 64:610-615.
34. Gurm HS, Lincoff AM, Kleiman NS, et al.: Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol 2004, 94:30-34.
35. McCullough PA, Lepor NE: The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 2005, 6:1-10.
36. Foley RN, Murray AM, Li S, et al.: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
37. Collins AJ: The hemoglobin link to adverse outcome. Advanced Studies in Medicine 2003, 3:S194-S197. Accessible online at http://www.jhasim.com/.
38. Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
39. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003, 107:223-225.
40. Silverberg DS, Wexler D, Blum M, et al.: Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001, 21(suppl 3):S236-S240.
41. Silverberg DS, Wexler D, Blum M, et al.: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003, 18:141-146.
42. Metivier F, Marchais SJ, Guerin AP, et al.: Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000, 15(suppl 3):14-18.
43. Satoh K, Kagaya Y, Nakano M, et al.: Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006, 113:1442-1450.
44. George J, Goldstein E, Abashidze A, et al.: Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005, 68:299-306.
45. Calvillo L, Latini R, Kajstura J, et al.: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003, 100:4802-4806.
46. Parsa CJ, Matsumoto A, Kim J, et al.: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.
47. Fiordaliso F, Chimenti S, Staszewsky L, et al.: A non-erythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005, 102:2046-2051.